Literature DB >> 24740429

Antidepressant and antioxidative effect of Ibuprofen in the rotenone model of Parkinson's disease.

Tiago Zaminelli1, Raísa Wendhausen Gradowski, Taysa Bervian Bassani, Janaína Kohl Barbiero, Ronise M Santiago, Daniele Maria-Ferreira, Cristiane Hatsuko Baggio, Maria A B F Vital.   

Abstract

Idiopathic Parkinson's disease is a neurodegenerative disorder that affects approximately 1 % of the population over 55 years of age. The disease manifests itself through motor and nonmotor symptoms induced mainly by the neurodegeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc). The possible mechanisms involved in this pathology include mitochondrial dysfunction, neuroinflammation, and oxidative stress. The present study evaluated the effects of the nonselective cyclooxygenase inhibitor ibuprofen on motor and depressive-like behavior induced by rotenone in rats. Rotenone (2.5 mg/kg, i.p., for 10 days) decreased tyrosine hydroxylase immunoreactivity in the SNpc, and ibuprofen treatment (15 mg/kg, p.o., for 22 days) blocked this impairment. We also found that rotenone-induced motor deficits (hypolocomotion) and depressive-like behavior, and ibuprofen was able to reverse these deficits. In addition to motor and nonmotor behaviors, we evaluated oxidative stress induced by rotenone. Rotenone administration depleted glutathione levels in the hippocampus and reduced catalase activity in both the hippocampus and striatum. Post treatment with ibuprofen blocked the depletion of glutathione induced by rotenone and increased the basal levels of this antioxidant in the striatum. Ibuprofen also restored catalase activity. The neuroprotective effects of ibuprofen against toxicity induced by rotenone appear to be attributable to its antioxidant properties, in addition to cyclooxygenase inhibition.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24740429     DOI: 10.1007/s12640-014-9467-y

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  64 in total

1.  Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia.

Authors:  W G Kim; R P Mohney; B Wilson; G H Jeohn; B Liu; J S Hong
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

2.  Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone.

Authors:  Sheila M Fleming; Chunni Zhu; Pierre-Olivier Fernagut; Arpesh Mehta; Cheryl D DiCarlo; Ronald L Seaman; Marie-Françoise Chesselet
Journal:  Exp Neurol       Date:  2004-06       Impact factor: 5.330

3.  Pesticide/environmental exposures and Parkinson's disease in East Texas.

Authors:  Amanpreet S Dhillon; G Lester Tarbutton; Jeffrey L Levin; George M Plotkin; Larry K Lowry; J Torey Nalbone; Sara Shepherd
Journal:  J Agromedicine       Date:  2008       Impact factor: 1.675

4.  Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depression.

Authors:  Nicoletta Brunello; Silvia Alboni; Giacomo Capone; Cristina Benatti; Joan M C Blom; Fabio Tascedda; Philippe Kriwin; Julien Mendlewicz
Journal:  Int Clin Psychopharmacol       Date:  2006-07       Impact factor: 1.659

5.  Synthetic combined superoxide dismutase/catalase mimetics are protective as a delayed treatment in a rat stroke model: a key role for reactive oxygen species in ischemic brain injury.

Authors:  K Baker; C B Marcus; K Huffman; H Kruk; B Malfroy; S R Doctrow
Journal:  J Pharmacol Exp Ther       Date:  1998-01       Impact factor: 4.030

Review 6.  COX-2 and neurodegeneration in Parkinson's disease.

Authors:  P Teismann; M Vila; D-K Choi; K Tieu; D C Wu; V Jackson-Lewis; S Przedborski
Journal:  Ann N Y Acad Sci       Date:  2003-06       Impact factor: 5.691

7.  Sodium salicylate protects against rotenone-induced parkinsonism in rats.

Authors:  Sindhu K Madathil; Saravanan S Karuppagounder; Kochupurackal P Mohanakumar
Journal:  Synapse       Date:  2013-03-27       Impact factor: 2.562

8.  Nonsteroidal anti-inflammatory drugs potentiate 1-methyl-4-phenylpyridinium (MPP+)-induced cell death by promoting the intracellular accumulation of MPP+ in PC12 cells.

Authors:  Norimitsu Morioka; Kei Kumagai; Katsuya Morita; Shigeo Kitayama; Toshihiro Dohi
Journal:  J Pharmacol Exp Ther       Date:  2004-05-06       Impact factor: 4.030

9.  The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine.

Authors:  N Müller; M J Schwarz; S Dehning; A Douhe; A Cerovecki; B Goldstein-Müller; I Spellmann; G Hetzel; K Maino; N Kleindienst; H-J Möller; V Arolt; M Riedel
Journal:  Mol Psychiatry       Date:  2006-02-21       Impact factor: 15.992

10.  Superoxide as an intracellular radical sink.

Authors:  C C Winterbourn
Journal:  Free Radic Biol Med       Date:  1993-01       Impact factor: 7.376

View more
  16 in total

1.  Neurotoxin mechanisms and processes relevant to Parkinson's disease: an update.

Authors:  Juan Segura-Aguilar; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2015-01-29       Impact factor: 3.911

2.  Ibuprofen targets neuronal pentraxins expresion and improves cognitive function in mouse model of AlCl3-induced neurotoxicity.

Authors:  Anum Jamil; Aamra Mahboob; Touqeer Ahmed
Journal:  Exp Ther Med       Date:  2015-12-10       Impact factor: 2.447

Review 3.  Inflammatory markers and depression in Parkinson's disease: a systematic review.

Authors:  Luis Guilherme Ramanzini; Luís Fernando Muniz Camargo; Juliana Oliveira Freitas Silveira; Guilherme Vargas Bochi
Journal:  Neurol Sci       Date:  2022-08-30       Impact factor: 3.830

Review 4.  Impact of Plant-Derived Flavonoids on Neurodegenerative Diseases.

Authors:  Silvia Lima Costa; Victor Diogenes Amaral Silva; Cleide Dos Santos Souza; Cleonice Creusa Santos; Irmgard Paris; Patricia Muñoz; Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2016-03-07       Impact factor: 3.911

Review 5.  Neuroinflammatory responses in Parkinson's disease: relevance of Ibuprofen in therapeutics.

Authors:  Ashish Singh; Pratibha Tripathi; Sarika Singh
Journal:  Inflammopharmacology       Date:  2020-10-14       Impact factor: 4.473

6.  Vanillin Attenuated Behavioural Impairments, Neurochemical Deficts, Oxidative Stress and Apoptosis Against Rotenone Induced Rat Model of Parkinson's Disease.

Authors:  Chinnasamy Dhanalakshmi; Udaiyappan Janakiraman; Thamilarasan Manivasagam; Arokiasamy Justin Thenmozhi; Musthafa Mohamed Essa; Ameer Kalandar; Mohammed Abdul Sattar Khan; Gilles J Guillemin
Journal:  Neurochem Res       Date:  2016-04-02       Impact factor: 3.996

7.  Indoleamine-2,3-Dioxygenase/Kynurenine Pathway as a Potential Pharmacological Target to Treat Depression Associated with Diabetes.

Authors:  Isabella Caroline da Silva Dias; Bruno Carabelli; Daniela Kaori Ishii; Helen de Morais; Milene Cristina de Carvalho; Luiz E Rizzo de Souza; Silvio M Zanata; Marcus Lira Brandão; Thiago Mattar Cunha; Anete Curte Ferraz; Joice Maria Cunha; Janaina Menezes Zanoveli
Journal:  Mol Neurobiol       Date:  2015-12-15       Impact factor: 5.590

8.  Ibuprofen abates cypermethrin-induced expression of pro-inflammatory mediators and mitogen-activated protein kinases and averts the nigrostriatal dopaminergic neurodegeneration.

Authors:  Ashish Singh; Pratibha Tripathi; Om Prakash; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2015-12-12       Impact factor: 5.590

9.  Impact of ibuprofen and peroxisome proliferator-activated receptor gamma on emotion-related neural activation: A randomized, placebo-controlled trial.

Authors:  Kelly T Cosgrove; Rayus Kuplicki; Jonathan Savitz; Kaiping Burrows; W Kyle Simmons; Sahib S Khalsa; T Kent Teague; Robin L Aupperle; Martin P Paulus
Journal:  Brain Behav Immun       Date:  2021-05-27       Impact factor: 19.227

10.  Geroprotective and Radioprotective Activity of Quercetin, (-)-Epicatechin, and Ibuprofen in Drosophila melanogaster.

Authors:  Ekaterina Proshkina; Ekaterina Lashmanova; Eugenia Dobrovolskaya; Nadezhda Zemskaya; Anna Kudryavtseva; Mikhail Shaposhnikov; Alexey Moskalev
Journal:  Front Pharmacol       Date:  2016-12-23       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.